Vergent Bioscience Announces Publication in The Annals of Surgical Oncology
Vergent Bioscience, a clinical-stage biotechnology company developing a tumor-targeted imaging platform, announced that data published in The Annals of Surgical Oncology (ASO) demonstrated clinical utility of abenacianine, the company’s investigational intraoperative molecular imaging (IMI) agent.
7/28/2026